|

ACADIA PHARMACEUTICALS INC (ACAD)

US0042251084 - Common Stock

22.02  -0.1 (-0.45%)

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (11/28/2023, 10:12:43 AM)

22.02

-0.1 (-0.45%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)11-02 2023-11-02/amc
Earnings (Next)02-26 2024-02-26/amc
Ins Owners0.51%
Inst Owners94.08%
Market Cap3.61B
Shares163.73M
PEN/A
Fwd PE31.15
Dividend YieldN/A
Analysts75.83
IPO05-27 2004-05-27
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACAD Daily chart

Company Profile

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The company is headquartered in San Diego, California and currently employs 511 full-time employees. The company went IPO on 2004-05-27. Its clinical-stage development are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis and neuropsychiatric symptoms in central nervous system disorders. Its pipeline includes NUPLAZID, Trofinetide, ACP-204 and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a treatment for Parkinson's Disease Psychosis. Trofinetide is a treatment for Rett Syndrome. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. ACP-204 is a treatment for Alzheimer’s Disease Psychosis. The company also owns rights to NNZ-2591 in both Rett and Fragile X syndrome.

Company Info

ACADIA PHARMACEUTICALS INC

12830 El Camino Real, Suite 400

San Diego CALIFORNIA 92130

P: 18585582871.0

CEO: Stephen R. Davis

Employees: 511

Website: https://acadia.com/

ACAD News

News Imagea day ago - Acadia Pharmaceuticals Inc.Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
News Image7 days ago - Acadia Pharmaceuticals Inc.Acadia Pharmaceuticals Announces Change in Research and Development Leadership
News Image14 days ago - Acadia Pharmaceuticals Inc.Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Image14 days ago - Market News VideoACAD Makes Bullish Cross Above Critical Moving Average
News Image20 days ago - InvestorPlace3 Biotech Stocks With the Strongest Clinical Pipelines

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

News Image26 days ago - Seeking AlphaAcadia Pharma GAAP EPS of -$0.40 beats by $0.05, revenue of $211.7M beats by $22.08M (NASDAQ:ACAD)

Acadia Pharma beats earnings expectations with record revenues from DAYBUE and NUPLAZID, and provides positive outlook for 2023.

ACAD Twits

Here you can normally see the latest stock twits on ACAD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example